ReviewHuman vaccines & immunotherapeutics2026
Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus remains a primary cause of severe dehydrating diarrhea in children globally, particularly in low- and middle-income countries (LMICs). While live-attenuated oral vaccines have significantly reduced the disease burden, their efficacy is particularly reduced in conditions characterized by malnutrition, intestinal dysbiosis, and environmental enteric dysfunction (EED). This review examines a diverse range of technologies, including lipid, polymeric, and metallic nanoparticles, as well as virus-like particles (VLPs) and pseudovirus nanoparticles (PVNPs), and analyzes their potential for enhanced antigen stability, targeted delivery, and potent immunogenicity. Unlike conventional formulations, these next-generation platforms can be designed as highly immunogenic injectable vaccines to cross the hostile intestinal environment or as protective oral carriers that protect antigens from degradation. Thus, the strategic integration of nanotechnology into rotavirus vaccine design could offer a transformative path to achieving sustained protection and overcoming the biological barriers that currently limit the success of live-attenuated vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.